TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
4.980
-0.110 (-2.16%)
At close: Jun 9, 2026, 4:00 PM EDT
5.09
+0.11 (2.22%)
After-hours: Jun 9, 2026, 6:33 PM EDT
TransCode Therapeutics Employees
TransCode Therapeutics had 12 employees as of December 31, 2025. The number of employees increased by 5 or 71.43% compared to the previous year.
Employees
12
Change (1Y)
5
Growth (1Y)
71.43%
Revenue / Employee
n/a
Profits / Employee
-$3,641,348
Market Cap
4.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 12 | 5 | 71.43% | 12 | 0 |
| Dec 31, 2024 | 7 | -3 | -30.00% | 7 | 0 |
| Sep 30, 2024 | 8 | -2 | -20.00% | 8 | 0 |
| Dec 31, 2023 | 10 | -9 | -47.37% | 10 | 0 |
| Dec 31, 2022 | 19 | 10 | 111.11% | 19 | 0 |
| Dec 31, 2021 | 9 | 3 | 50.00% | 8 | 1 |
| Sep 30, 2021 | 7 | 1 | 16.67% | 7 | 0 |
| Jun 30, 2021 | 6 | 0 | - | 2 | 4 |
| Mar 31, 2021 | 6 | 0 | - | 2 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| CollPlant Biotechnologies | 39 |
| Aptevo Therapeutics | 33 |
| GeoVax Labs | 19 |
| Cardio Diagnostics Holdings | 17 |
| FibroBiologics | 15 |
| XTL Biopharmaceuticals | 10 |
| Mustang Bio | 4 |
RNAZ News
- 1 day ago - TransCode Therapeutics to Host R&D Webcast on June 18, 2026 - PRNewsWire
- 6 days ago - Transcode reports results from Phase 1a dose escalation trial with TTX-MC138 - TheFly
- 6 days ago - TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer - PRNewsWire
- 7 days ago - TransCode Therapeutics Proxy statement: Proxy filing - Filings
- 13 days ago - Transcode Therapeutics initiates Phase 2a clinical trial with TTX-MC138 - TheFly
- 13 days ago - TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer - PRNewsWire
- 14 days ago - TransCode Therapeutics Proxy statement: Proxy filing - Filings
- 25 days ago - TransCode Therapeutics Quarterly report: Q1 2026 - Filings